Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)

NCT07038200 is registered in ClinicalTrials.gov with Avidity Biosciences, Inc. as lead sponsor.

NCT NCT07038200
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07038200 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)
Lead sponsor
Avidity Biosciences, Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
June 10, 2025
Completion date
July 31, 2028
Enrollment
200 (estimated)
Sites
46

Conditions

As the registry lists them; a condition with its own page is linked.

facio-scapulo-humeral dystrophy, facioscapulohumeral dystrophy, facioscapulohumeral muscular dystrophy, facioscapulohumeral muscular dystrophy 1, facioscapulohumeral muscular dystrophy 2, facioscapulohumeral muscular dystrophy type 1 (fshd1), fascioscapulohumeral muscular dystrophy, fascioscapulohumeral muscular dystrophy type 1, fascioscapulohumeral muscular dystrophy type 2, fsh muscular dystrophy, fshd, fshd - facioscapulohumeral muscular dystrophy, fshd1, fshd2, landouzy dejerine dystrophy, landouzy-dejerine muscular dystrophy, landouzy-dejerine syndrome